Literature DB >> 1359577

Anxiolytic-like effects of the noncompetitive NMDA antagonist MK 801.

Z Xie1, R L Commissaris.   

Abstract

The present study examined the effects of the noncompetitive NMDA antagonist, MK 801 (dizocilpine), on behavior in the conditioned suppression of drinking (CSD) punished drinking paradigm, a repeated-measures conflict task. In daily 10- or 15-min sessions, water-restricted rats drank from a tube that was occasionally electrified (0.25- or 0.5-mA shocks signaled by a tone). Trained subjects (4 weeks of CSD testing) exhibited stable baselines for both punished (approximately 40 or 100 shocks received/session at the 0.5- and 0.25-mA shock intensities, respectively) and unpunished (approximately 15 ml/session water intake at either shock intensity) responding. Over a wide range of doses, (+) MK 801 did not increase punished responding when administered using a 10-min, 4-h, or 48-h pretreatment. However, at a 24-h pretreatment (+) MK 801 (0.04-0.4 mg/kg, IP) produced a dramatic and dose-dependent increase in punished responding. The "inactive" (-) isomer of MK 801 did not produce a significant anxiolytic-like effect in the CSD paradigm at doses up to 2 mg/kg when tested using a 24-h pretreatment. These data suggest that the anticonvulsant agent (+) MK 801 also may exert antianxiety effects in humans.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1359577     DOI: 10.1016/0091-3057(92)90178-i

Source DB:  PubMed          Journal:  Pharmacol Biochem Behav        ISSN: 0091-3057            Impact factor:   3.533


  10 in total

1.  Young investigator award recipient.

Authors:  Z Xie
Journal:  J Mol Neurosci       Date:  2005       Impact factor: 3.444

2.  Termination of pseudopregnancy in the rat alters the response to progesterone, chlordiazepoxide, and MK-801 in the elevated plus-maze.

Authors:  Daniel Bitran; Steven M Solano
Journal:  Psychopharmacology (Berl)       Date:  2005-02-08       Impact factor: 4.530

3.  Crocins, the active constituents of Crocus Sativus L., counteracted ketamine-induced behavioural deficits in rats.

Authors:  Georgia Georgiadou; Vasilios Grivas; Petros A Tarantilis; Nikolaos Pitsikas
Journal:  Psychopharmacology (Berl)       Date:  2013-10-06       Impact factor: 4.530

Review 4.  Hippocampal NMDA receptors and anxiety: at the interface between cognition and emotion.

Authors:  Christopher Barkus; Stephen B McHugh; Rolf Sprengel; Peter H Seeburg; J Nicholas P Rawlins; David M Bannerman
Journal:  Eur J Pharmacol       Date:  2009-10-15       Impact factor: 4.432

5.  Group II metabotropic glutamate receptor type 2 allosteric potentiators prevent sodium lactate-induced panic-like response in panic-vulnerable rats.

Authors:  Philip L Johnson; Stephanie D Fitz; Eric A Engleman; Kjell A Svensson; Jeffrey M Schkeryantz; Anantha Shekhar
Journal:  J Psychopharmacol       Date:  2012-08-21       Impact factor: 4.153

Review 6.  Advances in the treatment of anxiety: targeting glutamate.

Authors:  Asher B Simon; Jack M Gorman
Journal:  NeuroRx       Date:  2006-01

7.  Reduced isolation-induced aggressiveness in mice following NAALADase inhibition.

Authors:  L A Lumley; C L Robison; B S Slusher; K Wozniak; M Dawood; J L Meyerhoff
Journal:  Psychopharmacology (Berl)       Date:  2003-11-21       Impact factor: 4.530

8.  Kappa opioid agonists produce anxiolytic-like behavior on the elevated plus-maze.

Authors:  T H Privette; D M Terrian
Journal:  Psychopharmacology (Berl)       Date:  1995-04       Impact factor: 4.530

9.  Effects of nano and conventional zinc oxide on anxiety-like behavior in male rats.

Authors:  Mozhgan Torabi; Mahnaz Kesmati; Hooman Eshagh Harooni; Hosein Najafzadeh Varzi
Journal:  Indian J Pharmacol       Date:  2013 Sep-Oct       Impact factor: 1.200

10.  Association of oxidative stress to the genesis of anxiety: implications for possible therapeutic interventions.

Authors:  Waseem Hassan; Carlos Eduardo Barroso Silva; Imdad Ullah Mohammadzai; Joao Batista Teixeira da Rocha; Landeira-Fernandez J
Journal:  Curr Neuropharmacol       Date:  2014-03       Impact factor: 7.363

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.